Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00585975 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of Bromfenac Ophthalmic Solution

A Phase 2 study of Cataract Surgery, sponsored by Bausch & Lomb Incorporated.

Completed
Registry status
Phase 2
Development phase
568
Enrollment target
1
Study location

NCT00585975 is a Phase 2 study of Cataract Surgery that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 568 participants, above the 65-participant average among 7 other Cataract Surgery trials with a reported enrollment target (774% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00585975, a Phase 2 study of Cataract Surgery, has completed, sponsored by Bausch & Lomb Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
568 participants
Enrollment target
1
Study location

Study Summary

This is a safety and efficacy study of bromfenac ophthalmic solution

Conditions Studied

Interventions

  • DRUG bromfenac ophthalmic solution

Study Locations (1)

California

  • ISTA Pharmaceuticals, Inc. - Irvine

Trial Details

FieldValue
Enrollment Target 568 participants
Start Date 2007-10
Phase Phase 2

Sponsor

Bausch & Lomb Incorporated

174 total trials

What the Registry Record Tells You About NCT00585975

The ClinicalTrials.gov registry entry for NCT00585975 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 568 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 7 other Cataract Surgery trials with a reported enrollment target (774% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract Surgery appearing as the primary indexed condition, and to 1 intervention - of which bromfenac ophthalmic solution is the first listed.

NCT00585975 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00585975 about?

NCT00585975 is a clinical study titled "Efficacy and Safety of Bromfenac Ophthalmic Solution". This is a safety and efficacy study of bromfenac ophthalmic solution

What is the current status of trial NCT00585975?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 568 participants. The study started on 2007-10.

What conditions does trial NCT00585975 study?

This clinical trial studies the following conditions: Cataract Surgery.

What interventions are being tested in trial NCT00585975?

The interventions under investigation include: bromfenac ophthalmic solution (DRUG).

Who is sponsoring clinical trial NCT00585975?

This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00585975 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract Surgery

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.